Morgan Stanley Tricida, Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.14 - $12.49 $21,759 - $1.94 Million	155,422 Added 63.31%	400,926 $60,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $1.38 Million - $2.21 Million	162,416 Added 195.47%	245,504 $2.57 Million
Q2 2022 Oct 27, 2022	BUY	$7.31 - $11.85 $22,470 - $36,426	3,074 Added 3.84%	83,088 $805,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $11.85 $22,470 - $36,426	3,074 Added 3.84%	83,088 $805,000
Q1 2022 Oct 27, 2022	SELL	$7.35 - $10.63 $22,593 - $32,676	-3,074 Reduced 3.7%	80,014 $657,000
Q1 2022 May 13, 2022	BUY	$7.35 - $10.63 $309,199 - $447,182	42,068 Added 110.86%	80,014 $657,000
Q4 2021 Feb 14, 2022	SELL	$4.19 - $9.56 $2 Million - $4.57 Million	-478,004 Reduced 92.65%	37,946 $363,000
Q3 2021 Nov 15, 2021	BUY	$3.56 - $4.64 $1.84 Million - $2.39 Million	515,950 New	515,950 $2.39 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.